Skip to main content
Jeffrey Toretsky, MD, Pediatric Hematology & Oncology, Washington, DC

JeffreyToretskyMD

Pediatric Hematology & Oncology • Washington, DC

Professor; Molecular Oncology Program Co-leader, Lombardi Comprehensive Cancer Center (LCCC), Division Chief Pediatric Adolescent and Young Adult Heme/Onc Medstar Georgetown University Hospital

Join to view full profile

Dr. Toretsky is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Toretsky's full profile

Already have an account?

  • Office

    3800 Reservoir Rd Nw
    web: toretsky.georgetown.edu
    Washington, DC 20007
    Phone+1 202-444-7599

Education & Training

  • National Cancer Institute
    National Cancer InstituteFellowship, Pediatric Hematology/Oncology, 1991 - 1994
  • Virginia Commonwealth University Health System
    Virginia Commonwealth University Health SystemResidency, Pediatrics, 1989 - 1991
  • Duke University Hospital
    Duke University HospitalInternship, Pediatrics, 1988 - 1989
  • University of Minnesota Medical School
    University of Minnesota Medical SchoolClass of 1988

Certifications & Licensure

  • DC State Medical License
    DC State Medical License 2002 - 2024
  • PA State Medical License
    PA State Medical License 2014 - 2016
  • MD State Medical License
    MD State Medical License 1991 - 2011
  • NC State Medical License
    NC State Medical License 1988 - 1999
  • American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

  • Fellow National Academy of Inventors, 2018
  • Elected Member The American Society for Clinical Investigation, 2007

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Author Correction: EWS–FLI1 Increases Transcription to Cause R-loops and Block BRCA1 Repair in Ewing Sarcoma  
    Kimberly Stegmaier, Stephen L Lessnick, Jeffrey A Toretsky, Nature

Press Mentions

  • DC Hospital’s Comprehensive Program Extends Beyond Medical Care to Help Young Cancer Patients
    DC Hospital’s Comprehensive Program Extends Beyond Medical Care to Help Young Cancer PatientsMay 17th, 2022
  • Adolescent and Young Adult Cancer Survivors Benefit from Area’s Only Program to Support Their Unique Needs
    Adolescent and Young Adult Cancer Survivors Benefit from Area’s Only Program to Support Their Unique NeedsApril 25th, 2022
  • Oncternal Therapeutics Announces Presentation of Two Abstracts at ASCO 2021 Virtual Meeting
    Oncternal Therapeutics Announces Presentation of Two Abstracts at ASCO 2021 Virtual MeetingApril 28th, 2021
  • Join now to see all

Grant Support

  • Novel Compounds To Inactivate Oncogenic Fusion ProteinsNational Cancer Institute2009–2012
  • Isolation And Small Molecule Targeting Of Ewing'S Sarcoma Stem CellsNational Cancer Institute2008–2011
  • YK-4-279 Specifically Targets ETS Family Fusion-Protein Cancers In Clinical TrialNational Cancer Institute2010
  • Signaling Pathways That Determine Ewings Sarcoma OutcomeNational Cancer Institute2004–2008
  • Biacore T100: ProteomicsNational Center For Research Resources2006
  • Biacore T100: Prostate CancerNational Center For Research Resources2006
  • Biacore T100: CancerNational Center For Research Resources2006
  • Biacore T100: Breast CancerNational Center For Research Resources2006
  • Biacore T100National Center For Research Resources2006
  • AKT Inhibitors To Treat Ewing'S SarcomaNational Cancer Institute2004–2005
  • Role Of IGF Signaling Upon Ewings Sarcoma PatientNational Cancer Institute2002–2003
  • Role Of IGF Signaling Upon Ewings Sarcoma PatientNational Cancer Institute2001

Dr. Jeffrey Toretsky, Dr. Jeffrey Toretsky, MD, Dr. J Toretsky